Revdofilimab

瑞芙利单抗

Report date: 2022/07/04 19:38:02

Base Information

Drug NameRevdofilimab

Drug Alias NameABBV-368 I-O Monoclonal AntibodyABBV-368PR-1628103

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionAnti-Tumor necrosis factor receptor superfamily member 4

TargetsTumor necrosis factor receptor superfamily member 4

Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesTaiwanPuerto Rico +[10]

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesAbbvie Inc

China Registration ClassN/A

Active CompaniesAbbvie Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungTriple Negative Breast Neoplasms

Inactive IndicationsHead and Neck NeoplasmsNeoplasms

ATC CodeN/A